Wall Street Zen downgraded shares of Polyrizon (NASDAQ:PLRZ – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings lowered shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on Polyrizon
Polyrizon Stock Performance
Polyrizon Company Profile
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Featured Stories
- Five stocks we like better than Polyrizon
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
